Stryker: Expanding Breast Reconstruction Leadership Warrants Premium Valuation and Buy Rating

In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on Stryker, with a price target of $412.00.

Ryan Zimmerman has given his Buy rating due to a combination of factors tied to Stryker’s established and expanding presence in the breast reconstruction market. He notes that Stryker is not entering this space from scratch, but rather building on years of capabilities acquired through Novadaq and Invuity, including fluorescent imaging platforms and illuminated retractor technologies that are already integrated into Stryker’s broader endoscopy offering. The company’s recent acquisition of MOLLI Surgical further broadens its breast surgery toolkit with a precise lesion-localization marker, reinforcing management’s clear strategic intent to deepen its footprint in this niche. Zimmerman interprets Stryker’s decision to form a dedicated breast-focused sales force and highlight this business on recent earnings calls as a signal of continued investment and potential for further portfolio expansion, including through additional M&A.

Zimmerman’s valuation work also underpins the Buy rating. His $412 price target is derived from applying a premium earnings multiple of 24.5x to his 12–24 month EPS estimate, which is above the current trading multiple and meaningfully higher than that of large-cap medtech peers. He argues that Stryker merits this valuation premium because of its consistent track record of execution and its sustained, above-peer growth profile. In his view, the combination of a differentiated set of breast reconstruction technologies, an expanding commercial infrastructure in this segment, and a history of successful integration and innovation supports both Stryker’s growth outlook and the justification for a higher multiple versus the sector, resulting in his Buy recommendation.

In another report released yesterday, Morgan Stanley also maintained a Buy rating on the stock with a $445.00 price target.

Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SYK in relation to earlier this year.